ARPIM’s Board of Directors has new president

The Romanian Association of International Medicines Producers appointed Calin Galaseanu as president, after being elected by the association’s General Assembly which met on January 9, ARPIM informs.

Galaseanu, who was member of ARPIM’s Bord in 2013, currently holds the Country Manager position at Bristol-Myers Squibb (BMS), having over 15 years of experience in the pharmaceutical industry. Doctor by profession, Galaseanu held management positions within Schering AG Romania, as well as leadership positions for the past seven years within BMS, before taking the lead of the company in April 2012. He also has international expertise in the field, holding business management roles within BMS Netherlands.

Discussing about his future mission as ARPIM’s President, Galaseanu said he believes ‘that the main mission I have as ARPIM’s President is that of consolidating the relations with the authorities and the other partners and to create together a performing health system, without ignoring that the core is the Romanian patient. Thus, the member-companies of ARPIM provide the authorities and their partners with their expertise in order to support the development of a health system, beneficial to patients and, at the same time, of a business environment ethical, predictable and transparent.’, according to a press release of the association.

The other members of ARPIM’s new Board are Pascal Prigent, Vice-President and GSK’s General Manager, Radu Rasinar, Vice-President and General Manager of AstraZeneca, Elena Mitova - General Manager of Novartis Pharma Services Romania, Jacopo Murzi – General Manager of both J&J Romania and Janssen Romania, Gabor Staniszlav – General Manager of Amgen Romania and Luca Visini – General Manager of Eli Lilly, all as members.

ARPIM is the association supporting the common objectives of the most important 28 international pharmaceutical companies, producers of original medicines, which operate in Romania. These companies’ operations represent over 70 percent of the Romanian pharmaceutical market.